Pacemakers: How They Work and When They Are Needed

Pacemakers are small implantable electronic devices designed to regulate abnormal heart rhythms by delivering precisely timed electrical impulses to the heart muscle. They occupy a central role in the management of bradyarrhythmias and certain conduction disorders, conditions where the heart beats too slowly or erratically to sustain adequate circulation. This page covers the device types, the mechanisms by which pacemakers function, the clinical scenarios that prompt implantation, and the thresholds that guide physician decision-making. The broader landscape of cardiology care and oversight provides context for understanding where pacemaker therapy fits within the specialty.

Definition and Scope

A pacemaker consists of two primary components: a pulse generator containing a battery and microprocessor circuitry, and one or more electrode leads that deliver electrical stimuli directly to cardiac tissue. The pulse generator is typically implanted subcutaneously in the pectoral region, while leads are threaded transvenously through the subclavian or cephalic vein into the right atrium, right ventricle, or both.

The U.S. Food and Drug Administration (FDA) classifies pacemakers as Class III medical devices under 21 CFR Part 870, subjecting them to the most rigorous premarket approval pathway. The FDA's Center for Devices and Radiological Health (CDRH) maintains regulatory oversight over pacemaker design, labeling, and post-market surveillance.

Pacemakers are classified by a standardized five-letter code established by the Heart Rhythm Society (HRS) and the British Pacing and Electrophysiology Group (BPEG), commonly referred to as the NBD or NASPE/BPEG Generic (NBG) code. The first letter designates the chamber paced, the second the chamber sensed, and the third the response to sensing — forming the basis for describing all pacemaker programming modes.

How It Works

The fundamental operation of a pacemaker relies on continuous sensing of intrinsic cardiac electrical activity and conditional delivery of pacing stimuli when that activity falls below a programmed threshold rate.

The pacing cycle operates in four phases:

1. Sensing — The lead electrodes detect the heart's intrinsic electrical depolarization. If a native beat occurs within the programmed escape interval, the pacemaker inhibits stimulus delivery.
2. Rate determination — The microprocessor compares detected intervals against the lower rate limit (LRL), typically programmed between 50 and 70 beats per minute at baseline implantation.
3. Stimulus delivery — If no intrinsic beat is detected within the escape interval, a pacing pulse is delivered at a programmed energy output, measured in milliamperes (mA) or volts (V) and pulse width in milliseconds.
4. Capture confirmation — The delivered impulse must achieve electrical capture — depolarization of the myocardium — confirmed by the presence of a paced beat on electrocardiogram.

Modern devices incorporate rate-responsive pacing (the "R" designation in the NBG code), using accelerometers or minute ventilation sensors to increase pacing rate during physical activity. This feature is particularly relevant for patients with chronotropic incompetence, a condition where the sinus node fails to increase heart rate appropriately with exertion.

Device configurations differ by the number of leads and chambers involved:

Leadless pacemakers — such as the Medtronic Micra device, which received FDA approval — are implanted directly into the right ventricle via femoral vein catheterization and eliminate transvenous leads entirely, reducing certain complication profiles documented in peer-reviewed literature published in the New England Journal of Medicine.

Common Scenarios

Pacemaker implantation is indicated across a defined set of clinical conditions where the cardiac conduction system fails to maintain an adequate spontaneous rhythm.

Sinus Node Dysfunction (Sick Sinus Syndrome): The sinoatrial (SA) node fails to generate consistent impulses, producing symptomatic bradycardia, sinus pauses, or alternating bradycardia-tachycardia. The American College of Cardiology (ACC) and American Heart Association (AHA) clinical practice guidelines assign a Class I recommendation (pacing is indicated) for symptomatic bradycardia attributable to sinus node dysfunction.

Atrioventricular (AV) Block: Conduction between atria and ventricles is delayed or blocked at the AV node or bundle of His. Third-degree (complete) AV block, where atrial and ventricular activity are entirely dissociated, carries a Class I pacing indication regardless of symptom status, per ACC/AHA guidelines. Second-degree Mobitz Type II block, which carries a high risk of progression to complete block, also receives a Class I recommendation. These rhythm disturbances are explored in greater depth on the atrial fibrillation and arrhythmias reference page.

Heart Failure with Dyssynchrony: Patients with reduced left ventricular ejection fraction (LVEF) ≤35% and a QRS duration ≥150 milliseconds with left bundle branch block morphology qualify for cardiac resynchronization therapy (CRT) under ACC/AHA heart failure guidelines. CRT pacemakers coordinate ventricular contraction to improve hemodynamic efficiency.

Post-Surgical or Procedural Bradycardia: Certain cardiac surgeries, including valve repair and septal defect correction, carry risk of AV node injury. Temporary or permanent pacing may be required when conduction does not recover within 5 to 7 days postoperatively, per established surgical cardiology practice parameters.

Decision Boundaries

The threshold for permanent pacemaker implantation is governed by published guideline documents, particularly the ACC/AHA/HRS guidelines on cardiac pacing, and by individualized clinical assessment. Not every bradycardia warrants a device.

Symptom correlation is required for most Class I indications. A resting heart rate of 45 beats per minute in a trained endurance athlete without symptoms does not meet guideline criteria for pacing. Conversely, a heart rate of 50 beats per minute with syncope, presyncope, or severe exercise intolerance typically does.

Key threshold criteria from ACC/AHA guidelines include:

• Symptomatic bradycardia with documented heart rates below 40 beats per minute during symptoms
• Sinus pauses exceeding 3.0 seconds associated with symptoms
• Chronotropic incompetence with a heart rate response below 80% of age-predicted maximum during exercise testing and documented functional limitation

Contraindications and deferral conditions include:

• Bradycardia caused by reversible etiologies (medication toxicity, hypothyroidism, electrolyte disturbances, vagal reactions) — these require treatment of the underlying cause before device implantation is considered
• Asymptomatic first-degree or Mobitz Type I (Wenckebach) AV block in the absence of associated symptoms or structural disease

Device programming, follow-up intervals, and remote monitoring standards are addressed by the Heart Rhythm Society's expert consensus documents on device follow-up. The regulatory context for cardiology page details the FDA and CMS frameworks that govern pacemaker implantation facility requirements and reimbursement standards.

Electromagnetic interference (EMI) considerations — including device interactions with MRI scanners, arc welding equipment, and certain industrial machinery — are addressed through device labeling required under FDA 21 CFR Part 870.3610. Most contemporary pacemakers carry conditional MRI labeling, permitting scanning under specified protocol conditions. Patients and managing clinicians should review manufacturer labeling and consult the living with a pacemaker or ICD reference for activity and safety guidance.

References

• U.S. FDA — Center for Devices and Radiological Health: Cardiovascular Devices
• 21 CFR Part 870 — Cardiovascular Devices (eCFR)
• American College of Cardiology (ACC) Clinical Guidelines
• American Heart Association (AHA) — Clinical Practice Guidelines
• Heart Rhythm Society (HRS) — Clinical Resources and Guidelines
• NASPE/BPEG Generic Pacemaker Code — Heart Rhythm Society Reference
• [Centers for Medicare & Medicaid Services (CMS) — Coverage Determinations for Cardiac Pacemakers](https://www.cms.gov/medicare-

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)